The FDA has granted accelerated approval to talquetamab-tgvs (Talvey) for the treatment of adult patients with r/r MM who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Here, CD38 is linked to Miyoshi myopathy.